Amakem, a Belgian kinase platform company focusing on ophthalmology, has appointed Steve Pakola as chief medical officer and George Lasezkay to its board as an independent director.
Pakola was previously chief medical officer at ThromboGenics, a biopharmaceutical company focused on developing ophthalmic medicines, where he played a pivotal role in driving the development of ThromboGenics’ lead product, ocriplasmin, from initial concept through to regulatory submission.
Lasezkay was previously corporate vice president of corporate development and assistant general counsel for Allergan, a pharmaceutical and medical aesthetics company. In these positions, he was responsible for corporate strategy as well as licensing, r&d collaboration and acquisition transactions involving both products and companies. He currently serves as an advisor to a number of public and private biotechnology companies developing therapies for ophthalmic conditions.
